NasdaqCM - Nasdaq Real Time Price USD

VYNE Therapeutics Inc. (VYNE)

1.8400

-0.0200

(-1.08%)

At close: April 23 at 4:00:00 PM EDT

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE’s management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday,

GlobeNewswire last month

VYNE
-1.08%
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

VYNE Therapeutics ( NASDAQ:VYNE ) Full Year 2024 Results Key Financial Results Net loss: US$39.8m (loss widened by 42...

Simply Wall St. last month

VYNE
-1.08%
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025Expected cash runway into 2H 2026 BRIDGEWATER, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announ

GlobeNewswire last month

VYNE
-1.08%
VYNE Therapeutics to Participate in March Investor Conferences

BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE’s management will participate in two investor conferences in March. Details are as follows: TD Cowen 45th Annual Health Care Conference, Boston, MAConference Date: March 4, 2025Format

GlobeNewswire 2 months ago

VYNE
-1.08%
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designed to provide key insights into VYN202’s potential across a range of chronic, immune-mediated diseases BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated

GlobeNewswire 2 months ago

VYNE
-1.08%
3 US Penny Stocks To Watch With Market Caps Over $20M

As U.S. markets face pressure from rising yields and inflation concerns, investors are re-evaluating their strategies to navigate these challenging conditions. While the term "penny stocks" may seem outdated, it still signifies smaller or emerging companies that could offer substantial growth potential. By focusing on those with strong financial foundations, investors can uncover opportunities in this segment of the market that might be overlooked by others.

Simply Wall St. 2 months ago

VYNE
-1.08%
BOSC

ZEPP
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in mid-2025“Repibresib” approved as the non-proprietary name for VYN201 by USAN BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions w

GlobeNewswire 3 months ago

VYNE
-1.08%
US Penny Stocks To Watch In December 2024

As the U.S. equities market stumbles toward the end of 2024, with the Dow and S&P 500 on track to post monthly losses, investors are increasingly looking for opportunities beyond large-cap stocks. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or less-established companies that can offer significant value potential. By focusing on those with robust financials and growth potential, investors might uncover promising opportunities in these overlooked segments...

Simply Wall St. 3 months ago

ARTW

SKLZ

VYNE
-1.08%
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data

H.C. Wainwright notes VYNE Therapeutics (VYNE) disclosed positive topline data from the MAD portion of its Phase 1a SAD/MAD trial assessing VYN202 in healthy volunteers. VYN202 is the company’s orally administrated BETi with strong specificity for the BD2 domain of BRD4. After reviewing the data, the firm maintains VYN202 represents significant clinical and value generating potential for the company and the stock. Wainwright thinks the data, in tandem with encouraging Phase 1 SAD data, robustly

TipRanks 3 months ago

VYNE
-1.08%
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitorsVYN202 demonstrated robust pharmacodynamic activity including evidence of target engagement and significant inhibition of inflammatory biomarkers relevant

GlobeNewswire 3 months ago

VYNE
-1.08%
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target VYNE is pioneering the development of BET inhibitors in large inflammation and immunology, or I&I, opportunities, notes the analyst, who adds that the class has well-understood relevance in oncology, but its potential in I&I is “a more recent revelation largely owed to efforts” by VYNE. The company’s lead program, VYN201, is a topical BET inhibitor that the firm sees having high odds of emerging as the next

TipRanks 5 months ago

VYNE
-1.08%
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

VYNE Therapeutics ( NASDAQ:VYNE ) Third Quarter 2024 Results Key Financial Results Net loss: US$12.2m (loss widened by...

Simply Wall St. 5 months ago

VYNE
-1.08%
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024 BRIDGEWATER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediat

GlobeNewswire 5 months ago

VYNE
-1.08%
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 6 months ago

VYNE
-1.08%
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and inflammatory biomarkers Dosing has begun in the MAD portion of the trial with results expected in Q4 2024 BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing

GlobeNewswire 7 months ago

VYNE
-1.08%
VYNE Therapeutics to Participate in September Investor Conferences

BRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that management will participate in two investor conferences in September: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9-11, 2024, New York, NYFormat: One-on-one investor

GlobeNewswire 7 months ago

VYNE
-1.08%
VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

VYNE Therapeutics ( NASDAQ:VYNE ) Second Quarter 2024 Results Key Financial Results Net loss: US$9.40m (loss narrowed...

Simply Wall St. 8 months ago

VYNE
-1.08%
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected in Q3 and Q4 2024, respectivelyBalance sheet expected to fund key clinical milestones for VYN201 and VYN202 through the end of 2025 BRIDGEWATER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused o

GlobeNewswire 8 months ago

VYNE
-1.08%
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced GB Patent No. 2621505 entitled “Pyrrolopyridone derivatives useful in the treatment of inflammatory disorders, immune disorders and cancer” has been granted by the United Kingdom’s Intellectual Property Off

GlobeNewswire 9 months ago

VYNE
-1.08%
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year

From what we can see, insiders were net buyers in VYNE Therapeutics Inc.'s ( NASDAQ:VYNE ) during the past 12 months...

Simply Wall St. 9 months ago

VYNE
-1.08%

Performance Overview

Return	VYNE	S&P 500 (^GSPC)
YTD	-45.07%	-8.60%
1-Year	-20.69%	+6.02%
3-Year	-77.73%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Participate in March Investor Conferences

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

3 US Penny Stocks To Watch With Market Caps Over $20M

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

US Penny Stocks To Watch In December 2024

H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

VYNE Therapeutics initiated with a Buy at BTIG on I&I potential

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics to Participate in September Investor Conferences

VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year

Performance Overview